MANE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Veradermics Inc (MANE) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong analyst ratings, promising Phase 3 study, and potential to capture a significant share of a $30B market for hair loss treatments make it an attractive investment opportunity. While financials show a loss, the significant YoY improvement in net income and EPS indicates progress. Technical indicators also suggest a bullish trend, supporting the buy decision.
The MACD is positive and contracting, indicating bullish momentum. RSI is neutral at 61.908, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near resistance levels (R1: 77.675), with a pre-market price of 74.75, suggesting potential upside.
Strong analyst ratings with multiple Buy/Outperform ratings and price targets ranging from $75 to $
High likelihood of success for the Phase 3 study of VDPHL01, which could become the first FDA-approved oral minoxidil for hair loss.
Large addressable market of $30B with unmet needs.
Innovative hybrid marketing strategy combining telehealth and direct-to-consumer campaigns.
Financials show no revenue and a net loss of -$28.2M in Q4 2025, though there is significant YoY improvement.
Lack of recent news or significant hedge fund/insider trading activity.
In Q4 2025, Veradermics reported no revenue but showed significant improvement in net income (-$28.2M, up 335.63% YoY) and EPS (-0.8, up 344.44% YoY). Gross margin remains at 0%.
Analysts are highly positive on Veradermics. Cantor Fitzgerald, Jefferies, Citi, and Leerink all initiated coverage with Buy/Outperform ratings. Price targets range from $75 to $85, and analysts highlight the company's innovative product pipeline, large market opportunity, and high likelihood of success in Phase 3 trials.
